Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.
Journal
Blood cancer discovery
ISSN: 2643-3249
Titre abrégé: Blood Cancer Discov
Pays: United States
ID NLM: 101764786
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
2
5
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
ppublish
Résumé
In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD-specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., p. 106 (9). See related article by Chang et al., p. 1684 (10).
Identifiants
pubmed: 37078891
pii: 726032
doi: 10.1158/2643-3230.BCD-22-0213
pmc: PMC10150292
doi:
Substances chimiques
mRNA Vaccines
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-175Commentaires et corrections
Type : CommentOn
Type : CommentOn
Informations de copyright
©2023 American Association for Cancer Research.
Références
Cancer Cell. 2022 Jun 13;40(6):587-589
pubmed: 35588736
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
N Engl J Med. 2022 Jul 28;387(4):374-376
pubmed: 35767474
Cancer Res Commun. 2022 Dec;2(12):1684-1692
pubmed: 36644323
Blood Cancer Discov. 2023 Mar 1;4(2):106-117
pubmed: 36511813
Cancer Discov. 2022 Apr 1;12(4):958-983
pubmed: 35179201
Science. 2022 Jul 15;377(6603):eabq1841
pubmed: 35699621
Signal Transduct Target Ther. 2022 Apr 28;7(1):141
pubmed: 35484110
Immunity. 2022 Oct 11;55(10):1779-1798
pubmed: 36182669